SHP2i联合AMG510的临床启动

Revolution Medicines宣布与Amgen合作探索SHP2抑制剂RMC-4630和AGM510联合治疗KRAS G12C突变的晚期实体瘤。在上周的Natue中的体外研究就发现AMG510和RM的另一个SHP2抑制剂RMC-4550联合时产生较强的协同效应抑制肿瘤细胞（打分越高协同越强），可能未来KRAS突变的治疗就是一个联合方案吧？

RM-4630可能改造自4550？

RM先前就RM4630的全球开发和赛诺菲达成了排他性合作。

先前在9月份RM就全部完成RM-4630联合cobimetinib (Cotellic®）在人体中的首例给药，该临床探索联合治疗在特定基因突变的患者中安全性和疗效，包括：KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations。

https://clinicaltrials.gov/ct2/show/NCT03989115

结果也可以拿4550来yy下：

不管是NF1 LOF还是KRAS amp，4550和MEKi都取得了很好的协同

November 4, 2019 – Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced an agreement with Amgen to evaluate the combination of RMC-4630, the company’s investigational SHP2 inhibitor, and AMG 510, Amgen’s investigational KRASG12C inhibitor.  Amgen will conduct a Phase 1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG 510 in combination with RMC-4630 in subjects with advanced solid tumors harboring the KRASG12C mutation.  Revolution Medicines will provide Amgen with clinical supply of RMC-4630 for the planned study.